Jennifer Fulk

Chief Financial Officer, principal financial officer, Kura Oncology, Inc.

In the seat. First published here October 28, 2026; built from records as of October 28, 2026.

Jennifer Fulk has been Chief Financial Officer, principal financial officer of Kura Oncology, Inc. since September 8, 2026, according to the company's filing of September 8, 2026.¹

The filing gives Jennifer Fulk's previous role as Chief Financial Officer at Soleno Therapeutics, Inc.¹ Jennifer Fulk joined from outside Kura Oncology, Inc., by the record's reading of the filing.¹ The filing shows an earlier chief financial officer seat, so this is not Jennifer Fulk's first.¹

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Kura Oncology, Inc. (KURA) Pharmaceutical Preparations	Chief Financial Officer, principal financial officer	In the seat	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

September 8, 2026effective
Kura Oncology, Inc. appointed Jennifer Fulk as Chief Financial Officer, principal financial officer, effective September 8, 2026. Profile of Troy E. Wilson, Ph.D., J.D..
Effective as of September 8, 2026, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”) appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E.
[1] Filing by Kura Oncology, Inc., filed with the SEC on September 8, 2026. Read the filing. The record at CFO Tribune.

Sources

Current report filed with the SEC, Kura Oncology, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 8, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jennifer Fulk wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.